Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Inks Marketing, Research Pact with DCL Medical Labs

NEW YORK (GenomeWeb News) – Third Wave Technologies today announced that it has teamed up with DCL Medical Laboratories to showcase its existing molecular diagnostic products and collaborate on research of future assays.
Under the agreement, Indianapolis-based DCL will offer Third Wave’s molecular diagnostic assays and have early access to new assays and equipment developed by the Madison, Wis.-based firm. In addition, Third Wave intends to establish a research and development lab at DCL for joint product research. The lab also will include a customer demonstration facility for Third Wave’s products.
DCL specializes in women’s health and human papillomavirus testing, which is also a focus for Third Wave.
Third Wave recently announced that it will submit data from clinical trials on its HPV molecular diagnostic tests with the US Food and Drug Administration in April. The firm will seek FDA clearance for a high-risk HPV test to be used in combination with a Pap test as well as an HPV genotyping test.
Terms of the alliance were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.